Positron Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2010
2011
2012
2013
2014
Sales/Revenue
4,623.00
6,663.00
2,801.00
1,630.00
1,466.00
Cost of Goods Sold (COGS) incl. D&A
4,564.00
6,386.00
1,972.00
1,206.00
1,362.00
Gross Income
59.00
277.00
829.00
424.00
104.00
SG&A Expense
14,503.00
4,669.00
5,551.00
3,210.70
2,847.00
EBIT
14,444.00
4,392.00
4,722.00
2,786.70
2,743.00
Unusual Expense
2,104.00
544.00
1,440.00
2,037.30
1,228.00
Non Operating Income/Expense
1,460.00
-
40.00
143.00
754.00
Interest Expense
43.00
1,185.00
1,753.00
2,137.00
1,823.00
Pretax Income
10,923.00
6,121.00
7,955.00
7,104.00
2,584.00
Consolidated Net Income
10,923.00
6,121.00
7,955.00
7,104.00
2,584.00
Net Income
10,923.00
6,121.00
7,955.00
7,104.00
2,584.00
Net Income After Extraordinaries
10,923.00
6,121.00
7,955.00
7,104.00
2,584.00
Net Income Available to Common
10,923.00
6,121.00
7,955.00
7,104.00
2,584.00
EPS (Basic)
8.00
4.00
2.51
1.96
0.28
Basic Shares Outstanding
1,783.70
1,966.40
3,163.20
3,630.90
9,261.20
EPS (Diluted)
6.12
3.11
2.51
1.96
0.28
Diluted Shares Outstanding
1,783.70
1,966.40
3,163.20
3,630.90
9,261.20
EBITDA
14,401.00
4,315.00
4,419.00
2,626.70
2,591.00

About Positron

View Profile
Address
1777 Maryland Avenue
Niagara Falls New York 14305
United States
Employees -
Website http://www.positron.com
Updated 07/08/2019
Positron Corp. is a nuclear medicine healthcare company specializing in the field of cardiac positron emission tomography imaging. It provides an economical, end-to-end solution for PET myocardial perfusion imaging through complementary product integration of PET imaging systems, radiopharmaceuticals and radioisotopes. The company was founded by Roman Oliynyk on December 20, 1983 and is headquartered in Westmont, IL.